The U.S. government is reportedly urging Germany to reassess its approach to drug pricing. This move comes amid broader discussions on pharmaceutical costs and access.
In addition to the focus on Germany, the FDA is experiencing significant upheaval, which may impact regulatory processes and approvals in the pharmaceutical sector.
The biotech industry is also in the spotlight, with ongoing clinical trials that could shape future treatments and therapies.